Clinical Trial

Patient-centered Dosage of Levothyroxine

Recruiting
View on ClinicalTrials.gov →
Summary
Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-06; most recent amendment 2025-09-03.
Status change: Not Yet Recruiting → Recruiting 2025-04-04
Trial Details
NCT Number NCT06455371
Lead Sponsor University Hospital of North Norway
Collaborators: SINTEF Health Research, Helseapps, Norinnova, Helse Nord
Conditions Hypothyroidism, Thyroid Cancer, Thyroid
Enrollment 240 participants
Start Date 2024-12-20
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-10